Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ANIP - ANI Pharmaceuticals Inc


IEX Last Trade
63.83
1.380   2.162%

Share volume: 365,554
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$62.45
1.38
2.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
28%
Profitability 15%
Dept financing 41%
Liquidity 75%
Performance 27%
Company vs Stock growth
vs
Performance
5 Days
3.36%
1 Month
-0.98%
3 Months
0.46%
6 Months
5.76%
1 Year
-1.33%
2 Year
76.94%
Key data
Stock price
$63.83
P/E Ratio 
55.14
DAY RANGE
$62.26 - N/A
EPS 
$1.26
52 WEEK RANGE
$48.20 - $70.50
52 WEEK CHANGE
-$0.01
MARKET CAP 
1.341 B
YIELD 
N/A
SHARES OUTSTANDING 
21.030 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$344,110
AVERAGE 30 VOLUME 
$455,626
Company detail
CEO: Patrick Walsh
Region: US
Website: http://www.anipharmaceuticals.com/
Employees: 280
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Recent news